Related Experiment Video

Updated: Jul 18, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity

Anthony T Power1, Jiahu Wang, Theresa J Falls

  • 1Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa Health Research Institute, Centre for Cancer Therapeutics, Ottawa, Ontario, Canada.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|December 14, 2006
PubMed

Insights

The adaptive immune response hinders oncolytic virus therapy. Encapsulating viruses in carrier cells overcomes this, improving cancer treatment efficacy by protecting viruses during delivery.

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Oncolytic viruses show promise for cancer therapy due to tumor-selective replication and lysis.
  • The host immune system, particularly adaptive immunity, presents a major challenge for effective systemic delivery of these viruses.
  • Antibody-mediated neutralization of oncolytic viruses significantly impairs their therapeutic potential.

Purpose of the Study:

  • To investigate the impact of adaptive immunity on the systemic delivery of oncolytic vesicular stomatitis virus (VSV).
  • To evaluate the efficacy of cell-based delivery platforms for oncolytic VSV to overcome immune-mediated barriers.
  • To assess the biodistribution and therapeutic potential of virus-loaded carrier cells in a murine tumor model.

Main Methods:

  • Utilized an immune-competent murine tumor model to study systemic VSV delivery.
  • Employed carrier cells to encapsulate and deliver VSV, shielding it from immune neutralization.
  • Administered VSV via naked virions versus carrier cells in animals with metastatic tumors.
  • Used whole-body molecular imaging to track the biodistribution of different carrier cell types.

Main Results:

  • Adaptive immune responses, primarily antibody neutralization, severely limit systemic delivery of naked VSV.
  • Delivery of VSV within carrier cells significantly enhanced therapeutic efficacy compared to naked virions.
  • Carrier cells effectively protected VSV from immune clearance, enabling targeted tumor cell infection.
  • Both syngeneic and xenogeneic carrier cells demonstrated efficacy in virus delivery, with distinct biodistribution patterns.

Conclusions:

  • Cell-based delivery platforms are crucial for overcoming immune-mediated obstacles in oncolytic virus therapy.
  • Encapsulating oncolytic viruses in carrier cells represents a viable strategy to improve systemic administration and therapeutic outcomes.
  • Further development of cell-based delivery systems is warranted to maximize the clinical potential of oncolytic virotherapy.

More Related Videos

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...